Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Preferred Stock Liabilities: 2019

Historic Preferred Stock Liabilities for Nurix Therapeutics (NRIX) over the last 1 years, with Nov 2019 value amounting to $48.2 million.

  • Nurix Therapeutics' Preferred Stock Liabilities was N/A to $48.2 million in Q4 2019 from the same period last year, while for Nov 2019 it was $48.2 million, marking a year-over-year change of. This contributed to the annual value of $48.2 million for FY2019, which is N/A change from last year.
  • According to the latest figures from FY2019, Nurix Therapeutics' Preferred Stock Liabilities is $48.2 million.
  • Nurix Therapeutics' Preferred Stock Liabilities' 5-year high stood at $48.2 million during FY2019, with a 5-year trough of $48.2 million in FY2019.
  • For the 1-year period, Nurix Therapeutics' Preferred Stock Liabilities averaged around $48.2 million, with its median value being $48.2 million (2019).